Ax­some cel­e­brates mi­graine PhI­II win, shift­ing eyes to­ward a pair of Q4 sub­mis­sions

6 years ago
R&D

Bris­tol My­ers Squibb, Ac­celeron rack up sec­ond OK for Re­blozyl, on­to block­buster sta­tus

6 years ago
Pharma
FDA+

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

6 years ago
People
Special

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

6 years ago
Bioregnum
FDA+

Ramp­ing up glob­al pro­duc­tion of remde­sivir, Gilead CEO Dan O’Day de­tails plans to dis­trib­ute 1.5M dos­es to fight ...

6 years ago
Pharma
Coronavirus

Lil­ly Asia Ven­tures co-leads $100M+ round for Chi­nese biotech and its late-stage lu­pus drug

6 years ago
Financing
China

GSK's asth­ma bi­o­log­ic Nu­cala is one step clos­er to ap­proval in key chron­ic rhi­nos­i­nusi­tis pop­u­la­tion

6 years ago
R&D

Servi­er bags an an­ti­body spe­cial­ist in its lat­est on­col­o­gy M&A deal with plans to add the plat­form tech

6 years ago
Deals
R&D

GSK vac­cine chief heads for AIDS vac­cine ini­tia­tive; Pfiz­er en­lists Sue Desmond-Hell­mann to its board of di­rec­tors

6 years ago
Peer Review

Ahead of US IPO, Leg­end Biotech adds $150M, top-tier in­vestors to back CAR-T pipeline

6 years ago
Financing
R&D

FDA re­ports short­age of se­da­tion drug used for putting Covid-19 pa­tients on ven­ti­la­tors

6 years ago
FDA+
Coronavirus

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

6 years ago
Financing
Bioregnum

In­vest­ing in the time of coro­n­avirus: the good, the bad and the hope­ful, as biotech VC firms close funds worth $3B

6 years ago
Financing
In Focus

Covid-19 roundup: Mod­er­na CEO Stéphane Ban­cel be­comes a bil­lion­aire; No­var­tis, In­cyte pitch Jakafi PhI­II to tack­le ...

6 years ago
R&D
Coronavirus

J&J gives pi­o­neer­ing stem cell biotech its first Big Phar­ma deal, part­ner­ing on iP­SC CAR-T and CAR-NK

6 years ago
Deals

Drug dis­cov­ery in the age of coro­n­avirus

6 years ago
Biotech Voices
Coronavirus

Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

6 years ago
R&D
Pharma

Sue Desmond-Hell­mann joins Pfiz­er board; Kite Phar­ma taps al­ly in push to ex­pand CAR-T

6 years ago
News Briefing

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from ...

6 years ago
Bioregnum
R&D

Dy­nacure se­cures $55M as their Io­n­is-de­vel­oped drug moves in­to clin­ic

6 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: Am­gen joins the race to de­vel­op a drug; Doc­tors, nurs­es em­ployed by Mer­ck, Lil­ly, Pfiz­er can pitch ...

6 years ago
Coronavirus

No­var­tis can­cels $1B sale of gener­ics af­ter an­titrust con­cerns forced de­lays

6 years ago
Deals

Step­ping out along­side ARCH's record raise, Flag­ship adds a $1.1B mon­ster fund of its own

6 years ago
Financing

ARCH chief Bob Nelsen has $1.5B to prove 2 sim­ple points: ‘We’re in the most in­no­v­a­tive time ever’ and ...

6 years ago
Financing
First page Previous page 847848849850851852853 Next page Last page
A service from the Financial Times